SLDB Q4 2021 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$19M-591.4% margin

Net Income

-$19M-590.0% margin

EPS (Diluted)

$-2.49

QoQ Revenue Growth

-10.8%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$22M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$232M

Total Liabilities

$24M

Stockholders' Equity

$208M

Cash & Equivalents

$119M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$19M	-$21M	+12.6%
Net Income	-$19M	-$21M	+12.9%